NDA 018962 · Hospira
Manganese Chloride In Plastic Container
Manganese Chloride · Injection
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Jun 26, 1986
Approved uses
1
Original approval plus efficacy supplements
Registered trials
15
3 Phase 3, 2 recruiting
FAERS reports
276
183 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 15, 2026.
INDICATIONS AND USAGE Manganese 0.1 mg/mL (Manganese Chloride Injection, USP) is indicated for use in adult patients as a supplement to intravenous solutions given for TPN. Administration helps to maintain manganese serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 26, 1986 Original approval · priority review
1 products under this application
- MANGANESE CHLORIDE IN PLASTIC CONTAINER · MANGANESE CHLORIDE EQ 0.1MG MANGANESE/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Manganese Chloride" as an intervention, any sponsor and status, largest first.
- A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck CancerPivotal-lookingCompleted
Galera Therapeutics, Inc.Industry
NCT02508389 · 223 participants · Start Oct 12, 2015 · Primary completion Sep 18, 2017
Drug: Low Dose GC4419: 30mg/day; High Dose GC4419: 90mg/day and 2 more · For: Radiation Induced Oral Mucositis
Sites: Phoenix, Arizona; Tucson, Arizona; Jonesboro, Arkansas · 64 sites in all
- A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian CancerPivotal-lookingRecruiting
Chinese PLA General HospitalAcademic, hospital or other
NCT07822646 · 120 participants (planned) · Start Oct 12, 2026 · Primary completion Apr 12, 2029
Drug: Manganese Chloride; Nab-paclitaxel and 3 more · For: Ovarian Cancer
Sites: Beijing, China; Tangshan, China; Taiyuan, China · 6 sites in all
- Probiotic Intervention in PCOSPivotal-lookingCompleted
Medical University of GrazAcademic, hospital or other
NCT04593459 · 112 participants · Start Nov 3, 2020 · Primary completion Oct 16, 2023
Drug: Metformin Hydrochloride · For: Polycystic Ovary Syndrome
Sites: Graz, Austria
NRG OncologyAcademic, hospital or other
NCT06532279 · 98 participants (planned) · Start Jun 23, 2025 · Primary completion Jan 1, 2027
Drug: Cisplatin; MnSOD Mimetic BMX-001 and 1 more · For: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 and 38 more
Sites: Gilbert, Arizona; Peoria, Arizona; Phoenix, Arizona · 153 sites in all
- Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney FunctionPivotal-lookingCompleted
Ascelia Pharma ABIndustry
NCT04119843 · 87 participants · Start Feb 19, 2020 · Primary completion Feb 17, 2023
Drug: Mangoral · For: Known or Suspected Focal Liver Lesions; Severe Renal Impairment
Sites: Scottsdale, Arizona; Los Angeles, California; Stanford, California · 60 sites in all
Chinese PLA General HospitalAcademic, hospital or other
NCT03989336 · 84 participants · Start Dec 23, 2020 · Primary completion May 22, 2022
Drug: Manganese Chloride; nab-paclitaxel and 2 more · For: Ovarian Cancer
Sites: Beijing, China
- An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic CancerStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT03989310 · 50 participants (planned) · Start Mar 1, 2019 · Primary completion May 31, 2021
Drug: Manganese Chloride; nab-paclitaxel and 2 more · For: Pancreatic Cancer
Sites: Beijing, China
Galera Therapeutics, Inc.Industry
NCT04529850 · 38 participants · Start Jun 30, 2020 · Primary completion Mar 10, 2021
Drug: Drug: GC4419; Cisplatin · For: Head and Neck Cancer; Oral Mucositis
Sites: Aalst, Belgium; Brasschaat, Belgium; Sint-Niklaas, Belgium · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue36
- headache28
- nausea25
- feeling abnormal21
- dizziness20
- pain20
- anxiety18
- diarrhoea18
- asthenia17
- drug ineffective17
- weight decreased17
- dyspnoea16
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 7 |
| 2010 | 7 |
| 2011 | 6 |
| 2012 | 8 |
| 2013 | 7 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 29 |
| 2017 | 17 |
| 2018 | 31 |
| 2019 | 31 |
| 2020 | 19 |
| 2021 | 16 |
| 2022 | 20 |
| 2023 | 12 |
| 2024 | 9 |
| 2025 | 8 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Hypersensitivity to metals in orthodontics.
Menezes LM, Campos LC, Quintão CC, et al. · Am J Orthod Dentofacial Orthop 2004 · Clinical Trial, Controlled Clinical Trial
- Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers.
Albiin N, Kartalis N, Bergquist A, et al. · MAGMA 2012 · Clinical Trial, Phase II, Randomized Controlled Trial
- Imaging liver metastases with a new oral manganese-based contrast agent.
Chabanova E, Logager V, Moller JM, et al. · Acad Radiol 2006 · Clinical Trial
- Comparison and estimation of effect on caries of daily supervised toothbrushing with a dentifrice containing sodium fluoride and a dentifrice containing potassium fluoride and manganese chloride. A three-year clinical test.
Koch G · Odontol Revy 1972 · Clinical Trial, Comparative Study
- MR colonography: optimized enema composition.
Luboldt W, Frohlich JM, Schneider N, et al. · Radiology 1999 · Clinical Trial, Comparative Study
- Lesion Visualization of an Oral Manganese Contrast Agent Compared to Unenhanced MRI and Gadobenate Dimeglumine in Patients Undergoing Liver Magnetic Resonance Imaging for Evaluation of Colorectal Cancer Metastases: Centralized Assessment of a Randomized, Crossover, Phase II Study.
Brismar TB, Kartalis N, Hettiarachchige N, et al. · Invest Radiol 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.